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A Rare Case of CYP2D6 and CYP2C19 Poor Metabolizer: A Pain Management
Dilemma.
Amna Shaikh MD, Murali Patri MD
Department of Anesthesiology, Pain and Perioperative medicine, Henry Ford Health System, Detroit, Michigan
Introduction
• Cytochrome P450 enzymes are essential for the metabolism of many
medications

Images
Table 1: Opioid Dosage and CYP Enzyme Deficiencies

• Genetic variability in these enzymes may influence a patient's response to
commonly prescribed drug classes. CYP2D6 and CYP2C19 enzymes are part
of the CYP450 enzyme

Post-operative Course
• Patient started complaining of intractable pain and due to lack of options in her
case for pain control, Anesthesiology staff was called, who considering her
known genetic deficiencies started her on intravenous (IV) ketamine infusion.
Due to the complexity of her postoperative pain management and the risk of
deleterious side effects, patient was admitted to the neurology intensive care unit
(ICU).
• On POD (post op day) 1: Pain team was consulted who continued her on IV
ketamine infusion. Her home medications for chronic pain and muscle spasms
which included pregabalin and clonazepam were restarted.
• On POD 2: Methocarbamol was started which was then increased from 750 mg
TID to 1 gm q6hr on POD 2. IV ketamine infusion was decreased to
0.5mg/kg/hr on POD 2.
• On POD 3: Ketamine infusion was decreased to 0.25mg/kg/hr and IV
acetaminophen 1G q 8 hrs. scheduled was started.
• On POD 4: Memantine 5 mg bid was started and ketamine infusion was later
discontinued. IV acetaminophen was continued.
• On POD 5: Patient reported improvement in pain as ketamine was transitioned
to memantine.
• On POD 6: Transferred to General Practice Unit (GPU) and was discharged
home on POD 7. The whole process required a six day close management in
ICU with pain service onboard to manage her intractable pain causing an
unpleasant experience for the patient.

• CYP2D6: responsible for the metabolism of most of the commonly prescribed
opiate medications
• CYP2C19: affects the metabolism of diazepam and carisoprodol, as well as
clopidogrel, proton pump inhibitors, and several antidepressants
• Poor metabolizers of these enzymes are extremely rare and when deficiency
present can cause severe and fatal side effects and overdose of drugs
• We herein report an unusual case of a poor metabolizer of medications
metabolized by CYP2D6 and CYP2C19 enzymes due to genetic deficiency
diagnosed on genetic testing

Clinical Vignette
Table 2: CYP2D6 is responsible for metabolism of most Opioids

• 56 year old female patient – PMHx of Ehlers-Danlos Syndrome (EDS) and
known deficiency of CYP2D6 and CYP2C19

Conclusion
• This case represents an unusual presentation where a patient with EhlersDanlos syndrome (EDS) has rare serious drug intolerance due to genetic
deficiency of CYP2D6 and CYP2C19 enzymes

• Patient presented for an elective Occipital to T3 fusion

• When such patients are undergoing surgery, involving pain service early in
the care can lead to a well formulated plan for postoperative pain
management

• The patient had a known deficiency of CYP2D6 and CYP2C19 diagnosed
through genetic testing, the presenting deficiencies caused several instances of
anaphylaxis, life threatening allergic reactions, serotonin syndrome and side
effects including delirium to medications including morphine, hydromorphone,
tramadol, codeine, diazepam, metoclopramide, ondansetron, amitriptyline, just
to name a few

• As seen in this case IV Ketamine is an excellent alternative medication for
acute pain control when opioids can not be used due to the above
mentioned genetic deficiencies as Ketamine’s major pathway is CYP3A4
and CYP2B6 enzymes

• On pre-operative visit patient did mention her concerns regarding postoperative pain management because of extensive allergy list to several pain
medications. Since patient also had history of difficult airway and failed
intubation in past due to cervical surgeries, focus was done on airway and the
presence of genetic deficiency somehow got ignored.
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• A pre-operative planning for post-operative pain control was not formulated
and pain team was not involved prior to surgery
• She underwent spinal surgery leading to a pain management dilemma starting
in the recovery room
Figure 3: Metabolism of Amitriptyline in liver.

Figure 4: Metabolism of Sertraline in liver.
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